Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654622 · ClinicalTrials.gov registry record
Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 175
- Enrollment target
NCT06654622 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 175 participants.
The verdict
NCT06654622 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 175 participants
- Enrollment target
Study Summary
This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2026-02-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06654622
The ClinicalTrials.gov registry entry for NCT06654622 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06654622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06654622 about?
NCT06654622 is a clinical study titled "Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer". This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for...
What is the current status of trial NCT06654622?
This trial is currently completed. The enrollment target is 175 participants. The study started on 2023-04-01. Estimated completion is 2026-02-18.
Who is sponsoring clinical trial NCT06654622?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.